Cure Arthritis Naturally

Cure Arthritis Naturally

Get Instant Access

1. Hoffman GS, Gross WL. Wegener's granulomatosis: clinical aspects. In: Hoffman GS, Weyand CM, eds. Inflammatory Diseases of Blood Vessels. New York, NY and Basel, Switzerland: Marcel Dekker, Inc, 2002:381-397.

2. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37(2):187-192.

3. Hoffman GS, Langford CA. Are there different forms of life in the antineutrophil cytoplasmic antibody universe? Ann Intern Med 2005; 143(9):683-685.

4. Cotch MF, Hoffman GS, Yerg DE, et al. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 1996; 39(1):87-92.

5. Devaney KO, Travis WD, Hoffman G, et al. Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 1990; 14 (6):555-564.

6. Weiss MA, Crissman JD. Renal biopsy findings in Wegener's granulomatosis: segmental necrotizing glomerulonephritis with glomerular thrombosis. Hum Pathol 1984; 15(10):943-956.

7. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116(6):488-498.

8. Lebovics RS. Sinonasal complications of vasculitic diseases. Cleve Clin J Med 2002; 69(suppl 2): SII152-SII154.

9. Gubbels SP, Barkhuizen A, Hwang PH. Head and neck manifestations of Wegener's granulomatosis. Otolaryngol Clin North Am 2003; 36(4):685-705.

10. Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998;41(9):1521-1537.

11. Vassilopoulos D, Niles JL, Villa-Forte A, et al. Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction. Arthritis Rheum 2003; 49 (2):151-155.

12. Savage CO, Winearls CG, Evans DJ, et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985; 56(220):467-483.

13. Lamprecht P, Trabandt A, Gross WL. Clinical and Immunological Aspects of Wegener's Granulomatosis (WG) and other syndromes resembling WG. Isr Med Assoc J 2000; 2(8):621-626.

14. Moins-Teisserenc HT, Gadola SD, Cella M, et al. Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet 1999; 354(9190):1598-1603. Erratum in Lancet 2000; 356(9224):170. Baycal C [corrected to Baykal C].

15. Langford CA, Talar-Williams C, Barron KS, et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114(6):463-469.

16. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349(1):36-44.

17. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52(8):2461-2469.

18. Stegeman CA, Tervaert JW, Sluiter WJ, et al Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120(1):12-17.

19. Rasmussen N. Management of the ear, nose, and throat manifestations of Wegener granulomatosis: an otorhinolaryngologist's perspective. Curr Opin Rheumatol 2001; 13(1):3—11.

20. Congdon D, Sherris DA, Specks U, et al. Long-term follow-up of repair of external nasal deformities in patients with Wegener's granulomatosis. Laryngoscope 2002; 112(4):731-737.

21. Kwan AS, Rose GE. Lacrimal drainage surgery in Wegener's granulomatosis. Br J Ophthalmol 2000; 84(3):329-331.

22. Kornblut AD, Wolff SM, Fauci AS. Ear disease in patients with Wegener's granulomatosis. Laryngoscope 1982; 92(7 Pt 1):713-717.

23. Hoffman GS, Thomas-Golbanov CK, Chan J, et al. Treatment of subglottic stenosis, due to Wegener's granulomatosis, with intralesional corticosteroids and dilation. J Rheumatol 2003; 30(5):1017-1021.

24. Eliachar I, Chan J, Akst L. New approaches to the management of subglottic stenosis in Wegener's granulomatosis. Cleve Clin J Med 2002; 69(suppl 2):SII149-SII151.

25. Langford CA, Sneller MC, Hallahan CW. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Arthritis Rheum 1996; 39(10):1754-1760.

26. Zakaluzny SA, Lane JD, Mair EA. Complications of tracheobronchial airway stents. Otolaryngol Head Neck Surg 2003; 128(4):478-488.

27. Mair EA. Caution in using subglottic stents for Wegener's granulomatosis. Laryngoscope 2004; 114 (11):2060-2061.

28. Gluth MB, Shinners PA, Kasperbauer JL. Subglottic stenosis associated with Wegener's granulomatosis. Laryngoscope 2003; 113(8):1304—1307.

29. Watts RA, Carruthers DM, Scott DJ. Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arthritis Rheum 1995; 25(1):28-34.

30. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78(1):26-37.

31. Lanham JG, Elkon KB, Pusey CD, et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63(2):65-81.

32. Nissim F, Von der Valde J, Czernobilsky B. A limited form of Churg-Strauss syndrome: ocular and cutaneous manifestations. Arch Pathol Lab Med 1982; 106(6):305-307.

33. Churg A, Brallas M, Cronin SR, et al. Formes frustes of Churg-Strauss syndrome. Chest 1995; 108 (2):320-323.

34. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143(9):632-638.

35. Greer JP, Kinney MC, Loughran TP Jr. T cell and NK cell lymphoproliferative disorders. Hematology (Am Soc Hematol Educ Program) 2001; 259-281.

36. Jaffe ES. Pathologic and clinical spectrum of post-thymic T-cell malignancies. Cancer Invest 1984; 2 (5):413-426.

37. Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20(1):103-111.

38. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, Nov, 1997. Ann Oncol 1999; 10(12):1419-1432.

39. Chim CS, Ma SY, Au WY. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103(1):216-221.

40. Nava VE, Jaffe ES. The pathology of NK-cell lymphomas and leukemias. Adv Anat Pathol 2005; 12 (1):27-34.

41. Kim K, Chie EK, Kim CW, et al. Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy. Jpn J Clin Oncol 2005; 35(1):1-5.

Was this article helpful?

0 0
Arthritis Relief Now

Arthritis Relief Now

When you hear the word arthritis, images of painful hands and joints comes into play. Few people fully understand arthritis and this guide is dedicated to anyone suffering with this chronic condition and wants relief now.

Get My Free Ebook

Post a comment